Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 24:12:2137-2143.
doi: 10.2147/OPTH.S180393. eCollection 2018.

Biosimilars in ophthalmology: "Is there a big change on the horizon?"

Ashish Sharma  1 , Prahalad Reddy  1 , Baruch D Kuppermann  2 , Francesco Bandello  3 , Anat Lowenstein  4
Affiliations
Review

Biosimilars in ophthalmology: "Is there a big change on the horizon?"

Ashish Sharma et al. Clin Ophthalmol. .

Abstract

Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in 2020 (though Regeneron has indicated that it might attempt to extend its US patent to June 2023 with additional patent claims), and their European patents will expire in 2022 and 2025. Aflibercept comes off patent in 2022 in People's Republic of China and Japan. As soon as each patent expires, biosimilar molecules could potentially come in the mainstream clinical practice as a more cost-efficient choice in the form of generic biosimilars. It is difficult to predict how significant this shift would be in terms of more cost-effective clinical management and how it will impact the care in developed and developing world. It is important for clinicians to have a clear understanding about ophthalmic biosimilars before the industry brings these molecules to the mainstream clinical use globally.

Keywords: Eylea®; Lucentis®; Razumab®; biosimilar; ophthalmology.

PubMed Disclaimer

Conflict of interest statement

Disclosure None of the authors have a direct financial interest in this manuscript, though the authors below have the following financial disclosures regarding their relationships with many of the companies whose products are discussed here or alternatively with competitors of companies whose products are mentioned here: Baruch D Kuppermann: Clinical Research – Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genen-tech, GSK, Novartis, Regeneron, ThromboGenics; Consultant – Aerpio, Alcon, Alimera, Allegro, Allergan, Ampio, Catalyst, Cell Care, Dose, Genentech, Novartis, Ophthotech, Regeneron.Francesco Bandello: Clinical Research – Allergan, Bayer, Boehringer Ingelheim, Hoffman La Roche, Novartis, NTC Pharma, Sifi, Sooft, ThromboGenics, Zeiss.Dr Anat Lowenstein acts as a consultant/advisor for the following companies: Allergan, Bayer, Beyeonics, ForSight Labs, Notal Vision, Novartis, Alcon, Almira.Dr Ashish Sharma acts as aconsultant/advisor for the following companies: Allergan, Bayer, Novartis, Intas. The authors report no other conflicts of interest in this work.

References

    1. Entine J. FDA balances costs, patient safety in the biologics and per-sonalized medicine revolution. Forbes. 2012. [Accessed September 23, 2018]. Available from: https://www.forbes.com/sites/jonentine/2012/07/23/fda-balances-costs-pat....
    1. Dimasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33. - PubMed
    1. Hospira.com [homepage on the Internet] Lake Forest, IL: Hospira; [Accessed May 16, 2018]. Available from: https://www.hospira.com.au/en/about_hospira/biologics/developing_biosimi....
    1. investor.regeneron.com [homepage on the Internet] Eastview, MN: Regeneron; [Accessed May 16, 2018]. Available from: http://investor.regeneron.com/releasedetail.cfm?releaseid=1047691.
    1. gminsights.com [homepage on the Internet] Ocean View, DE: Global Market Insights; [Accessed May 16, 2018]. Available from: https://www.gminsights.com/industry-analysis/diabetic-retinopathy-market....